A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1

מצבים רפואיים

Advanced Solid Tumors · Ewing Sarcoma · Hepatocellular Carcinoma (HCC) · Biliary Tract Cancer (BTC)

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

The City of Hope National Medical Center, Duarte, California, United States
Contact: Study coordinator (Kathryn Zurcher) · kzurcher@coh.org · 626-218-3029
Contact: Principal Investigator (Daneng Li)
Hoag Memorial Hospital, Newport Beach, California, United States
Contact: Study coordinator (Holland Orndorff) · Holland.Orndorff@hoag.org · 949-764-7110
Contact: Principal Investigator (Alain Mita)
Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Kristina Goodwin) · kgoodwin@mgh.harvard.edu · 617-643-6256
Contact: Principal Investigator (Gregory Cote)
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Suzanne George) · Suzanne_George@dfci.harvard.edu · 877-338-7425
Contact: Principal Investigator (Suzanne George, MD)
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Pri Wartanian) · wartant@mskcc.org · 210-685-2159
Contact: Principal Investigator (Robert Maki)
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Kofi Effa Ababio) · KEAbabio@mdanderson.org · 346-725-3989
Contact: Principal Investigator (Jordi Rodon Ahnert)